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Abstract
Background: Placebo can have a significant therapeutic effect in patients with hand osteoarthritis (OA). This aim of
the study is to identify factors associated with a clinically meaningful placebo response in patients with hand OA.
Methods: This post-hoc analysis of two double-blind, placebo-controlled, randomized trials (RCTs) investigating the
efficacy of GCSB-5 or diacerein as treatments for hand OA analyzed the efficacy of a placebo. Clinical and laboratory
factors associated with a clinically meaningful response, defined as an improvement in the Australian/Canadian
Osteoarthritis Hand Index (AUSCAN) pain score > 10 at 4 weeks relative to baseline, were identified.
Results: The mean improvement in the AUSCAN pain score was − 6.0 ± 20.3, with marked variation between 143
hand OA patients (range: − 76.4 to 33.2). A clinically meaningful improvement was observed in 54 (37.8%) patients.
Placebo responders had worse AUSCAN pain scores (55.7 ± 19.7 vs. 43.6 ± 21.6, p = 0.001) and a worse AUSCAN
stiffness (68.2 ± 20.5 vs. 57.5 ± 24.5, p = 0.008) at baseline than non-responders. Improvements in pain correlated
with the baseline pain level (Pearson r = − 427, p < 0.001). Structural joint changes such as tender, swollen,
enlarged, or deformed joint counts did not differ between placebo responders and non-responders. In a
multivariable analysis, only baseline AUSCAN pain was associated with a clinically meaningful placebo response (OR:
1.054, 95% CI [1.019–1.089], p = 0.002).
Conclusions: High levels of pain at baseline are predictive of a clinically meaningful placebo response in patients
with hand OA. Further studies are needed to optimize and utilize the benefit of placebo responses in patients with
hand OA.
Keywords: Osteoarthritis, Hand, Placebo
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: leb7616@snu.ac.kr
A part of the work was presented at the 2019 ACR/ARP Annual Meeting
(Abstract # 694792).
1Department of Internal Medicine, Division of Rheumatology, Seoul National
University College of Medicine, 101 Daehak-ro, Jong no-gu, Seoul 03080,
South Korea
4Department of Molecular Medicine and Biopharmaceutical Sciences,
Graduate School of Convergence Science and Technology, Seoul National
University, Seoul, South Korea
Full list of author information is available at the end of the article
Park et al. BMC Musculoskeletal Disorders          (2021) 22:244 
https://doi.org/10.1186/s12891-021-04089-9
Background
Osteoarthritis (OA) of the hands is common in middle-
aged and elderly populations, especially women [1]. The
marked disability and reduced quality of life caused by
the disease are comparable with those caused by
rheumatoid arthritis (RA) [2, 3]. Pain can be especially
debilitating in patients with erosive hand OA, which is
characterized by painful swelling, and joint inflammation
as well as the subchondral bone erosions and marginal
osteophyte formation on radiographic images. The main
therapeutic approach to hand OA is to control symp-
toms by using a combination of non-pharmacological
and pharmacological interventions [4]; this is because,
unlike for RA, there are no effective disease-modifying
osteoarthritis drugs (DMOADs). To date, oral non-
steroidal anti-inflammatory drugs (NSAIDs), acetamino-
phen, or opioid-based analgesics constitute the mainstay
of treatment targeting pain control. Inflammatory cyto-
kines such as interleukin-1 (IL-1), tumor necrosis factor
alpha (TNF-α) may contribute to the degeneration of ar-
ticular cartilage matrix [5]. Therefore, treatment target-
ing inflammation and pro-inflammatory cytokines were
attempted. In a recent study, a short-term treatment
with low dose corticosteroid improved pain and signs of
inflammation in patients who experience a flare-up of
hand OA [6]. However, they and other medications, in-
cluding anti-tumor necrosis factor inhibitors and anti-
interleukin-1 antibody, show only minimal to moderate
effect sizes, emphasizing an unmet need for better treat-
ment modalities for hand OA [7–9].
A previous randomized clinical placebo-controlled trial
(RCT) involving patients with hand OA reported that
30.2% of patients in the placebo group demonstrated a
positive Outcome Measures in Rheumatology-OA Re-
search Society International (OMERACT-OARSI) re-
sponse at Week 4 [10], suggesting that placebo can have
a significant therapeutic effect [11]. In one meta-
analysis, the placebo response might account for about
75% of response to drugs commonly used in OA [12].
Boosting the intrinsic placebo response in OA treatment
might improve clinical care. For this, it might be import-
ant to identify factors associated with a susceptibility to
placebo effect [13]. However, it is unclear which patients
with hand OA will benefit most from this placebo effect.
In this post-hoc analysis of two RCTs, we aimed to iden-
tify factors associated with a clinically meaningful pla-
cebo response in patients with hand OA.
Methods
Study design
This post-hoc analysis was based on clinical and labora-
tory data from two prospective, double-blind, random-
ized, placebo-controlled trials designed to investigate the
efficacy and safety of GCSB-5 or diacerein for treating
hand OA; both studies were conducted in accordance
with the Declaration of Helsinki [10, 14]. In the first
RCT, 220 patients with hand OA according to the 1990
American College of Rheumatology (ACR) criteria for
hand OA [15], all of whom were aged > 40 years and had
pain exceeding 30/100 mm on a visual analog scale in
the preceding 48 h, were randomly assigned to receive
oral GCSB-5 (600mg) or placebo twice a day for 12
weeks [10]. In the second RCT, 86 patients with hand
OA according to the 1990 ACR for hand OA were ran-
domized to receive diacerein (50 mg) or placebo twice a
day [14]. All participating patients provided written in-
formed consent. The study was approved by the institu-
tional review boards of all participating centers and was
registered at ClinicalTrials.gov (study no: NCT01910116
and NCT00685542). The post-hoc analysis included 102
patients with hand OA that were in the placebo group of
the first RCT and 41 patients that were in the placebo
group of the second RCT; patients with available clinical
and laboratory parameters at baseline and at Week 4
were included in the analysis group (n = 143) (Fig. 1).
Outcome
The efficacy endpoints included changes in the following
variable from baseline: the AUSCAN pain score (0–100),
the AUSCAN stiffness score (0–100), the AUSCAN
function score (0–100), a patient global assessment (0–
100), a physician global assessment (0–100), and the
OMERACT-OARSI response criteria. A clinically signifi-
cant improvement in pain was defined as an improve-
ment in the AUCAN pain score of 10 (0–100) or more
[16]. Patients deemed to be OMERACT-OARSI re-
sponders when they showed an improvement relative to
baseline in pain or function domains of ≥50% with an
absolute change of ≥20, or an improvement relative to
baseline in at least two of three (pain, function, and pa-
tient global assessment) domains of ≥20% with an abso-
lute change of ≥10 [17].
Statistical analysis
An independent t-test and the Chi-squared test or Fish-
er’s exact test (as appropriate) were used to compare
placebo responders and non-responders in terms of
demographics and clinical variables. Normality of vari-
ables was examined using Kolmogorov-Smirnov test.
Correlations between pain and clinical parameters were
assessed using Pearson’s correlation. Multivariable logis-
tic regression analysis was performed to identify factors
associated with a clinically meaningful response. P < 0.05
was considered to indicate statistical significance. All
analyses were performed by using IBM SPSS Statistics
22 software. All statistical analyses were performed by
the authors.
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Fig. 1 Flow diagram. RCT, randomized controlled trial
Table 1 Baseline characteristics of patients with hand OA who received placebo in the two randomized controlled trials





Age, years 59.2 ± 8.0 61.7 ± 18.9 0.305
Female, n (%) 95 (93.1) 39 (95.1) 0.496
Weight, kg 59.1 ± 8.0 60.4 ± 8.9 0.398
Height, cm 157.0 ± 6.0 156.0 ± 6.3 0.348
Body mass index, kg/m2 23.9 ± 2.9 24.7 ± 2.8 0.129
Duration of hand OA, months 31.5 ± 47.7 60.4 ± 61.1 0.009
Baseline
AUSCAN pain score (1–100) 47.8 ± 19.8 48.9 ± 25.9 0.788
AUSCAN stiffness score (1–100) 60.6 ± 21.7 63.9 ± 27.6 0.504
AUSCAN function score (1–100) 45.7 ± 23.7 41.7 ± 27.1 0.382
Patient global assessment (1–100) 49.6 ± 15.9 60.8 ± 19.4 0.002
Physician global assessment (1–100) 41.0 ± 13.0 42.6 ± 10.5 0.471
Tender joint count 6.3 ± 5.1 5.5 ± 5 0.400
Swollen joint count 0.9 ± 2.4 0.0 ± 0.3 0.000
Palpable node count 5.2 ± 2.5 N/A
Deformed joint count 2.0 ± 1.7 N/A
Erythrocyte sedimentation rate, mm/hr 12.9 ± 9.4 16.1 ± 11.6 0.086
hs-CRP, mg/dL (normal < 0.5 mg/dL) 0.12 ± 0.26 0.21 ± 0.76 0.317







Data are presented as the mean (SD) or n (%). AUSCAN Australian/Canadian Osteoarthritis Hand Index; CRP C-reactive protein, ESR Erythrocyte sedimentation rate,
N/A Not available, NSAID Non-steroidal anti-inflammatory drug, OA Osteoarthritis, RCT Randomized controlled trial.
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Results
Patients’ characteristics
The mean age of the 102 patients with hand OA in RCT 1
and 41 patients in RCT 2 were 59.4 ± 8.0 years and 61.7 ±
18.9 years, respectively. Women were dominant in both
RCTs. The mean disease duration of patients in RCT 1
and those in RCT 2 were 31.5 ± 47.7months and 60.4 ±
61.1months, respectively. Baseline characteristics of pa-
tients including AUSCAN pain, stiffness and function
score were comparable between both groups (Table 1).
AUSCAN pain
The mean AUSCAN pain score at baseline was 47.8 ±
19.8 in RCT 1 and 48.9 ± 25.9 in RCT 2 (Table 1). In
RCT 1, the AUSCAN pain score was associated with the
AUSCAN stiffness score (r = 0.312, p < 0.001), the AUS-
CAN function score (r = 0.743, p < 0.001), the patient
global assessment (r = 0.393, p < 0.001), and the phys-
ician global assessment (r = 0.205, p = 0.039). However,
the AUSCAN pain score was not associated with the
tender joint count (r = 0.057, p = 0.567), the swollen joint
count (r = 0.032, p = 0.749), the enlarged joint count (r =
− 0.044, p = 0.659), or the deformed joint count (r=− 0.065,
p=0.515) at baseline. Similar correlations between baseline
AUSCAN pain and other clinical characteristics were observed
in RCT 2, except for TJC, which correlated with baseline
AUSCAN-pain (r=0.506, p=0.001) (Supplementary Table S1).
Factors associated with a significant placebo response
The overall improvement in the AUSCAN pain in 143
patients was − 6.0 ± 20.3. The mean improvement in the
AUSCAN pain score did not differ between RCT 1 and
RCT 2 (− 6.0 ± 19.7 vs. -6.1 ± 22.1, p = 0.944). The
change in pain varied markedly between patients, ran-
ging from − 76.4 to 33.2 in RCT 1 and − 59 to 46.0 in
RCT 2 from baseline (Fig. 2a). Patients in RCT 1 and
RCT 2 who received placebo showed a similar response
with respect to improved pain, stiffness, and function
scores. In addition, change in patient and physician glo-
bal assessments at week 4 were similar between RCTs.
At 4 weeks, 54 (37.8%) of the 143 patients showed a
clinically meaningful improvement (i.e., pain reduction
> 10) (Table 2). These patients had a worse AUSCAN
pain score at baseline (55.7 ± 19.7 vs. 43.6 ± 21.6, p =
Fig. 2 Placebo response. a Change in AUSCAN-pain at 4 weeks from the baseline in 102 patients in RCT 1 and 41 patients in RCT 2 were
depicted. Red dotted line marks the clinically meaningful response. b Correlation between pain, stiffness, and function at baseline and placebo
responses in 143 patients with hand osteoarthritis. Scatterplot represents the relation between the change in pain, stiffness and function and
their respective baseline value. Correlations were examined by using Pearson’s correlation analysis
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0.001), a worse AUSCAN stiffness (68.2 ± 20.5 vs. 57.5 ±
24.5, p = 0.008) than patients without clinical improve-
ment. The tender joint count (TJC), the swollen joint
count (SJC), the enlarged joint count, and the deformed
joint count did not differ between patients with or with-
out clinically meaningful improvement. More patients
showing clinically meaningful improvement used
tramadol-AAP at baseline than those not showing clin-
ical improvement (18.9% vs. 1.5%, respectively; p =
0.034). There was no difference between groups with re-
spect to other medications, including NSAIDs and glu-
cosamine (Table 2).
Strikingly, there was a correlation between improve-
ment in pain and level of pain at baseline (Pearson r = −
0.427, p < 0.001). In addition, change in stiffness and
function from baseline correlated with baseline stiffness
(Pearson r = − 0.425, p < 0.001) and baseline function
(Pearson r = − 0.474, p < 0.001), respectively (Fig. 2b).
Factors associated with a clinically meaningful placebo
response
A logistic regression analysis was performed to identify
factors associated with a clinically meaningful placebo
response. In a univariable analysis, baseline AUSCAN
pain (OR [95% CI] 1.028, [1.0105–1.0458], p = 0.002)
and baseline AUSCAN function (1.021 [1.005–1.0371],
p = 0.010) were associated with a better placebo re-
sponse. In a multivariable analysis, only baseline AUS-
CAN pain was associated with clinically meaningful
placebo response (1.054 [1.019–1.089], p = 0.002).
Discussion
This post-hoc analysis of two prospective, double-blind,
randomized, placebo-controlled studies shows that pla-
cebo yielded a clinically meaningful improvement in
about one third of patients with hand OA. This placebo
response was associated significantly with baseline pain,
but not with structural changes such as joint swelling or
osteophyte formation.
Hand OA is common, with a prevalence ranging from
29 to 76% [1, 18]. In half of patients, the disease will pro-
gress, leading to severe functional limitation and a serious
disease burden [19]. In the absence of effective DMOADs,
symptoms (i.e., pain, function and stiffness) are controlled
by NSAIDs, tramadol, and opioid analgesics. However, the
potential gastrointestinal and cardiovascular side effects of
these drugs limit long-term use [20–23].
Although pain associated with OA is caused by struc-
tural changes due to accelerated degeneration of articular
cartilage and secondary bone remodeling, pain signals are
ultimately perceived by the brain after intensive central
pain processing at multiple levels [24]. Consistent with
this, we found that pain at baseline was not associated
with structural changes such as swollen joints, nor was it
associated with osteophyte formation and joint deformity
(Supplementary Table S1). Pain correlated with the tender
joint count only in RCT 2. Rather, pain was more closely as-
sociated with subjective parameters such as the AUCAN
stiffness and function scores. Similarly, improvements in
AUSCAN stiffness and function scores correlated with base-
line stiffness and function, respectively. Taken together, not
only pain generation in joints, but also central pain process-
ing, might ultimately determine the level of pain and func-
tional impairment experienced by patients with hand OA.
Although the mean improvement in AUSCAN pain
was low, pain responses to placebo varied markedly
among the OA patients, ranging from − 76.4 - 33.2 from
baseline. Strikingly, high baseline pain, but not the
Table 2 Demographic and clinical characteristics of the 143
hand OA patients in randomized controlled trial 1 and 2






Age, years 58.1 ± 7.5 60 ± 8.2 0.164
Female 81 (91.0) 53 (98.1) 0.153
Weight, kg 59.1 ± 8.3 59.9 ± 8.3 0.606
Height, cm 157.3 ± 5.9 155.8 ± 6.2 0.150
BMI, kg/m2 23.9 ± 2.7 24.7 ± 3.1 0.105
OA duration, month 3.2 ± 4 3.5 ± 5.1 0.657
AUSCAN Pain 43.6 ± 21.6 55.7 ± 19.7 0.001
AUSCAN Stiffness 57.5 ± 24.5 68.2 ± 20.5 0.008
AUSCAN Function 41.7 ± 23.2 49.1 ± 26.6 0.083
Patient GA 51.1 ± 16 55.6 ± 19.9 0.158
Physician GA 40.1 ± 11.3 43.7 ± 13.6 0.084
Tender JC 5.8 ± 4.7 6.5 ± 5.7 0.426
Swollen JC 0.8 ± 2.4 0.5 ± 1.5 0.328
Enlarged JC a 5.1 ± 2.7 5.4 ± 2.2 0.622
Deformity JC a 2 ± 1.6 1.9 ± 1.9 0.658
ESR 0.17 ± 0.52 0.09 ± 0.13 0.291
CRP 13.4 ± 10.4 14.5 ± 9.6 0.533
Prior treatment
Tramadol-AAP a 3 (4.6) 7 (18.9) 0.034
Tramadol a 1 (1.5) 0 (0) 1.000
NSAIDs a 22 (33.8) 14 (37.8) 0.685
Diacerin a 2 (3.1) 1 (2.7) 1.000
Glucosamine a 9 (13.8) 4 (10.8) 0.765
Others a 1 (1.5) 2 (5.4) 0.297
Data are presented as the mean (SD) or n (%). P values were generated by
using an independent t-test (continuous variables) or the Chi-squared test
(categorical variables). a Data were not available in the placebo group of RCT
2. AUSCAN Australian/Canadian Osteoarthritis Hand Index, CRP C-reactive
protein, ESR Erythrocyte sedimentation rate, NSAID Non-steroidal anti-
inflammatory drug, OA Osteoarthritis. Joints according to ACR OA classification
criteria were evaluated.
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severity of structural joint changes, was associated
with a better placebo response (Table 1) [25]. This is
consistent with a prior observation demonstrating that
neither structural damage observed on ultrasound nor
clinical severity of OA are predictive of treatment re-
sponse [26]; this further supports the dissociation be-
tween treatment response and structural joint changes
in those with hand OA. Rather, we found that im-
provements in pain, function, and stiffness correlated
significantly with their respective baseline levels
(Fig. 1).
While baseline AUSCAN pain and function were asso-
ciated with a clinically meaningful placebo response, the
multivariable analysis identified only the baseline AUS-
CAN pain as the factor for the placebo response. Inter-
estingly, women with hand OA were 10 fold more likely
to have a positive placebo response (Table 3), consistent
with sex difference in the placebo response [27]. While
OA affects both men and women, women were domin-
ant in both RCTs, consistent with female dominance in
the recent trials with hand OA [6, 9]. This suggests that
women might suffer more from hand OA than men and
they, therefore, are more likely to seek medical attention.
Whether women with hand OA are more susceptible to
pain, placebo response or both needs further
investigation.
Placebo effect is not limited to hand OA and it de-
pends on the mode of delivery. In knee OA, intra-
articular and topical placebo elicited a greater placebo
response than oral placebo [28]. The placebo effect can
vary among OA sites since it was greater in knee OA
than in hip OA [29]. Taken together, all placebo are
not equal. However, it is still important to identify
additional factors associated with a treatment re-
sponse to optimize clinical care of OA patients. As
example, early radiographic features such as congru-
ent articular reduction and tiabial plateau alignment
were associated with a better pain improvement after
surgical treatment of displaced tibial plateau fractures
[30]. It is interesting that use of tramadol/AAP was
also associated with a better placebo response,
whereas NSAIDs and other medications were not.
Tramadol acts on central pain processing; it is a weak
agonist of the mu opiate receptor and inhibits both
serotonin and norepinephrine reuptake, thereby exert-
ing anti-nociceptive effects [31].
A previous study shows that in patients with chronic
pain and associated pain sensitization (such as those
with fibromyalgia), the retention rate for tramadol/AAP
is higher than that for placebo [32, 33]. Therefore, OA
patients with severe pain might have developed aberrant
central pain processing over time, resulting in increased
central sensitization [34]. OA patients who were taking
tramadol/AAP at baseline might benefit from anti-
nociceptive effects on central pain processing, making
them more susceptible to placebo effects. Indeed, dulox-
etine, which modifies central pain sensitization, is an ef-
fective treatment for knee OA [35]. The mechanism
Table 3 Factors associated with a clinically meaningful placebo response
Univariate Multivariate
Variables OR 95% CI P value OR 95% CI P value
Age 1.031 0.987–1.077 0.164 1.039 0.987–1.094 0.141
Gender (female) 5.235 0.636–43.068 0.124 10.552 0.931–119.633 0.057
Weight, kg 1.011 0.970–1.053 0.603
Height, cm 0.958 0.902–1.016 0.152 1.010 0.934–1.091 0.811
BMI 1.104 0.979–1.245 0.108 1.104 0.969–1.258 0.136
Ds duration 1.017 0.944–1.097 0.655
AUSCAN-Pain 1.028 1.010–1.046 0.002 1.054 1.019–1.089 0.002
AUSCAN-Function 1.021 1.005–1.037 0.010 0.974 0.947–1.001 0.058
AUSCAN-Stiffness 1.028 0.998–1.027 0.423
Physician global assessment 1.025 0.996–1.054 0.088 1.018 0.986–1.052 0.270
Patient global assessment 1.015 0.995–1.035 0.137 0.998 0.972–1.024 0.872
Tender JC 1.028 0.961–1.098 0.423
Swollen JC 0.914 0.762–1.097 0.334
CRP 0.444 0.08–2.474 0.355
ESR 1.011 0.978–1.045 0.531
Multivariate logistic regression was performed. Variables that showed association (p < 0.2) in the univariable analysis were included in the multivariable analysis.
AUSCAN Australian/Canadian Osteoarthritis Hand Index, BMI Body mass index, CI Confidence interval, CRP C-reactive protein, Ds Disease, ESR Erythrocyte
sedimentation rate, JC Joint count, NSAID Non-steroidal anti-inflammatory drug, OR Odds ratio, OA Osteoarthritis.
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underlying central pain processing in OA requires fur-
ther investigation.
It might be unethical to prescribe a placebo in routine
clinical practice. However, the inherent placebo effect of
any pharmacological and non-pharmacological treat-
ment could be optimized in routine clinical practice.
This is of particular importance since the placebo re-
sponse might account for about 75% of response to
drugs that are commonly used in OA treatment [12]. To
optimize this placebo effect, it might be crucial to iden-
tify patients who are more susceptible to a placebo re-
sponse. In this study, female gender and high baseline
pain were associated with a clinically significant placebo
response (Table 3). The question of whether a warm and
reassuring consultation, optimistic attitudes of health-
care providers, and positive relationships between pa-
tient and physician improve OA outcomes should be
investigated in future.
This study has several limitations. First, the lack of a con-
trol group that did not receive any treatment (even placebo)
makes estimating the placebo effect difficult. Second, we did
not consider depressive mood disorders and/or emotional or
physical stress, which might influence pain processing and so
placebo responses. Third, RCT 2 (41 patients in the placebo
arm) is too small to enable comparison of clinical parameters
between clinical responders and non-responders. However,
both RCT 1 and RCT 2 showed remarkably similar placebo
responses (Supplementary Table S2). Further studies are
needed to identify therapeutic and situational factors that im-
prove placebo responses.
Conclusions
The placebo effect can be significant in patients with
hand OA who have high pain levels at baseline. Further
studies are needed to understand the pathophysiology
and underlying mechanisms, and to optimize the pla-
cebo effect as an OA treatment in clinical practice.
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